Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy.

Fiche publication

Date publication

décembre 2020

Journal

Journal for immunotherapy of cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr AMARAL Teresa Maria

Tous les auteurs :
Turiello R, Capone M, Giannarelli D, Morretta E, Monti MC, Madonna G, Mallardo D, Festino L, Azzaro R, Levesque MP, Imhof L, Weide B, Amaral T, Chevrier M, Sucker A, Rutkowski P, Schadendorf D, Lebbe C, Luke JJ, Wistuba-Hamprecht K, Dummer R, Pinto A, Morello S, Ascierto PA

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33361405

Résumé

Inhibitors of immune checkpoint programmed cell death protein 1 (PD-1) receptor on T cells have shown remarkable clinical outcomes in metastatic melanoma. However, most patients are resistant to therapy. Production of extracellular adenosine, via CD73-mediated catabolism of AMP, contributes to suppress T-cell-mediated responses against cancer. In this study, we analyzed the expression and activity of soluble CD73 in sera of patients with melanoma undergoing anti-PD-1± cytotoxic T-lymphocyte-associated antigen 4 therapy.